Abstract 4075
Background
Cancer causes loss of muscle mass, which is associated with a poor prognosis. Chemotherapy could also reduce muscle mass. We investigated changes of skeletal muscle mass during palliative chemotherapy and its association of treatment outcomes in patients with advanced gastric cancer (AGC).
Methods
This retrospective study consisted of 91 consecutive patients who underwent first line palliative chemotherapy in AGC. Skeletal muscle area was measured at the level of the third lumbar vertebra using computed tomography scans taken before and after chemotherapy. We assessed changes in skeletal muscle index (SMI), body mass index (BMI), and body weight and compared the chemotherapy response and survival according to the changes of body composition.
Results
In total 91 patients, median age was 64 years (range, 31-87 years). 75.4% of patients were male and 45.1% were sarcopenia at baseline. Mean decrease of SMI from pre-chemotherapy to post-chemotherapy was -5.4 ± 5.3 cm2/m2 (P < 0.001), mean decrease of BMI was -0.6 ± 1.9 kg/m2 (p = 0.002), and mean decrease of body weight was -1.8 ± 5.3 kg (P = 0.002). Mean decrease of SMI for patient with objective response was -4.4 ± 5.4 cm2/m2, mean decrease of SMI with stable disease was -6.0 ± 5.2 cm2/m2 and mean decrease of SMI with progression was -5.4 ± 5.2 cm2/m2. Response to chemotherapy was not associated with decrease in SMI (p = 0.491). In multivariable analysis, sarcopenia at baseline (HR, 1.959; 95% CI, 1.190 to 3.225, p = 0.008), decreased SMI (HR, 1.747; 95% CI, 1.042 to 2.929; p = 0.034) and poor ECOG score (HR, 1.902; 95% CI, 1.081 to 3.346; p = 0.026) were significant poor prognostic factors for survival.
Conclusions
Skeletal muscle mass decreased significantly during chemotherapy in patients with AGC. However, response to chemotherapy was not associated with decrease in skeletal muscle mass. The decreased SMI was a poor prognostic factor in patients with AGC during first line palliative chemotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
860 - Dose differential modulation of the autophagic behavior of estrogen expressing breast carcinoma cells
Presenter: Mariam Fouad
Session: Poster Display session 1
Resources:
Abstract
2304 - Synthetic peptide of tumor–associated antigen L6 formulated with polymer-based adjuvant enhances anti-tumor effects in mice
Presenter: Shih-jen Liu
Session: Poster Display session 1
Resources:
Abstract
4419 - Improving detection level of somatic mosaicism in neurofibromatosis type 1
Presenter: Kristina Karandasheva
Session: Poster Display session 1
Resources:
Abstract
5283 - Preclinical pharmacokinetic/pharmacodynamic (PK/PD) relationship of ABN401, a highly selective Met inhibitor, in gastric and non-small-cell lung cancer models
Presenter: JooSeok Kim
Session: Poster Display session 1
Resources:
Abstract
5488 - Transcription factors of Snail family in the regulation of resistance of breast cancer cells to hypoxic conditions
Presenter: Alvina Khamidullina
Session: Poster Display session 1
Resources:
Abstract
5417 - Metastasis is impaired by endothelial-specific Dll4 loss-of-function through inhibition of epithelial-to-mesenchymal transition and reduction of cancer stem cells and circulating tumour cells
Presenter: Liliana Mendonça
Session: Poster Display session 1
Resources:
Abstract
5494 - Identification of novel and known FGFR gene fusions in Chinese non-small cell lung cancer
Presenter: Weixin Zhao
Session: Poster Display session 1
Resources:
Abstract
3412 - WNT pathway mutations (APC/CTNNB1) and immune checkpoint inhibitors (ICI) response in metastatic non-small cell lung cancer (NSCLC) patients.
Presenter: Francisco Javier Ros Montana
Session: Poster Display session 1
Resources:
Abstract
1815 - Leukocytosis as a negative prognostic factor in patients with lung cancer: Which subpopulation of leukocytes is responsible?
Presenter: Filip Kohutek
Session: Poster Display session 1
Resources:
Abstract
5022 - Identification of MET gene amplifications using next-generation sequencing in non-small cell lung cancer patients
Presenter: Sergi Clavé
Session: Poster Display session 1
Resources:
Abstract